Thrombosis, anticoagulation and outcomes in malignant superior vena cava syndrome

Roy Ratzon; Shlomit Tamir; Tal Friehmann; Nir Livneh; Elizabeth Dudnik; Alon Rozental; Orly Hamburger-Avnery; David Pereg; Estela Derazne; Baruch Brenner; Pia Raanani; Hugo ten Cate; Galia Spectre; Avi Leader

doi:10.1007/s11239-018-1747-6

Thrombosis, anticoagulation and outcomes in malignant superior vena cava syndrome

Roy Ratzon, Shlomit Tamir, Tal Friehmann, Nir Livneh, Elizabeth Dudnik, Alon Rozental, Orly Hamburger-Avnery, David Pereg, Estela Derazne, Baruch Brenner, Pia Raanani, Hugo ten Cate, Galia Spectre, Avi Leader^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Anticoagulation is often used in superior vena cava syndrome (SVCS) associated with cancer (i.e malignant SVCS), even without thrombosis, but its effect on outcomes has not been reported. We aimed to determine factors and outcomes associated with thrombosis and anticoagulation in malignant SVCS. Patients with malignant SVCS diagnosed on computerized tomography (CT) were retrospectively included, indexed at diagnosis and followed for 6 months using medical records. The cohort included 183 patients with malignant SVCS of which 153 (84%) were symptomatic. Thirty of the 127 patients (24%) with a reviewable baseline CT had thrombosis of the SVC or tributaries at diagnosis. Patients with baseline thrombosis more often had symptomatic SVCS (p

Original language	English
Pages (from-to)	121-128
Number of pages	8
Journal	Journal of Thrombosis and Thrombolysis
Volume	47
Issue number	1
DOIs	https://doi.org/10.1007/s11239-018-1747-6
Publication status	Published - Jan 2019

Keywords

Superior vena cava syndrome
Malignancy
Thrombosis
Anticoagulation
MANAGEMENT
OBSTRUCTION

Access to Document

10.1007/s11239-018-1747-6

Cite this

Ratzon, R., Tamir, S., Friehmann, T., Livneh, N., Dudnik, E., Rozental, A., Hamburger-Avnery, O., Pereg, D., Derazne, E., Brenner, B., Raanani, P., ten Cate, H., Spectre, G., & Leader, A. (2019). Thrombosis, anticoagulation and outcomes in malignant superior vena cava syndrome. Journal of Thrombosis and Thrombolysis, 47(1), 121-128. https://doi.org/10.1007/s11239-018-1747-6

@article{ec8afa1e6f8b40e69a9be60ee764e121,

title = "Thrombosis, anticoagulation and outcomes in malignant superior vena cava syndrome",

abstract = "Anticoagulation is often used in superior vena cava syndrome (SVCS) associated with cancer (i.e malignant SVCS), even without thrombosis, but its effect on outcomes has not been reported. We aimed to determine factors and outcomes associated with thrombosis and anticoagulation in malignant SVCS. Patients with malignant SVCS diagnosed on computerized tomography (CT) were retrospectively included, indexed at diagnosis and followed for 6 months using medical records. The cohort included 183 patients with malignant SVCS of which 153 (84%) were symptomatic. Thirty of the 127 patients (24%) with a reviewable baseline CT had thrombosis of the SVC or tributaries at diagnosis. Patients with baseline thrombosis more often had symptomatic SVCS (p",

keywords = "Superior vena cava syndrome, Malignancy, Thrombosis, Anticoagulation, MANAGEMENT, OBSTRUCTION",

author = "Roy Ratzon and Shlomit Tamir and Tal Friehmann and Nir Livneh and Elizabeth Dudnik and Alon Rozental and Orly Hamburger-Avnery and David Pereg and Estela Derazne and Baruch Brenner and Pia Raanani and {ten Cate}, Hugo and Galia Spectre and Avi Leader",

note = "Funding Information: Funding This work was supported by the Paul Davidoff Foundation for the Ofek Program in collaboration with the Tel-Aviv University. Publisher Copyright: {\textcopyright} 2018, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2019",

month = jan,

doi = "10.1007/s11239-018-1747-6",

language = "English",

volume = "47",

pages = "121--128",

journal = "Journal of Thrombosis and Thrombolysis",

issn = "0929-5305",

publisher = "Springer, Cham",

number = "1",

}

Ratzon, R, Tamir, S, Friehmann, T, Livneh, N, Dudnik, E, Rozental, A, Hamburger-Avnery, O, Pereg, D, Derazne, E, Brenner, B, Raanani, P, ten Cate, H, Spectre, G & Leader, A 2019, 'Thrombosis, anticoagulation and outcomes in malignant superior vena cava syndrome', Journal of Thrombosis and Thrombolysis, vol. 47, no. 1, pp. 121-128. https://doi.org/10.1007/s11239-018-1747-6

TY - JOUR

T1 - Thrombosis, anticoagulation and outcomes in malignant superior vena cava syndrome

AU - Ratzon, Roy

AU - Tamir, Shlomit

AU - Friehmann, Tal

AU - Livneh, Nir

AU - Dudnik, Elizabeth

AU - Rozental, Alon

AU - Hamburger-Avnery, Orly

AU - Pereg, David

AU - Derazne, Estela

AU - Brenner, Baruch

AU - Raanani, Pia

AU - ten Cate, Hugo

AU - Spectre, Galia

AU - Leader, Avi

N1 - Funding Information: Funding This work was supported by the Paul Davidoff Foundation for the Ofek Program in collaboration with the Tel-Aviv University. Publisher Copyright: © 2018, Springer Science+Business Media, LLC, part of Springer Nature.

PY - 2019/1

Y1 - 2019/1

N2 - Anticoagulation is often used in superior vena cava syndrome (SVCS) associated with cancer (i.e malignant SVCS), even without thrombosis, but its effect on outcomes has not been reported. We aimed to determine factors and outcomes associated with thrombosis and anticoagulation in malignant SVCS. Patients with malignant SVCS diagnosed on computerized tomography (CT) were retrospectively included, indexed at diagnosis and followed for 6 months using medical records. The cohort included 183 patients with malignant SVCS of which 153 (84%) were symptomatic. Thirty of the 127 patients (24%) with a reviewable baseline CT had thrombosis of the SVC or tributaries at diagnosis. Patients with baseline thrombosis more often had symptomatic SVCS (p

AB - Anticoagulation is often used in superior vena cava syndrome (SVCS) associated with cancer (i.e malignant SVCS), even without thrombosis, but its effect on outcomes has not been reported. We aimed to determine factors and outcomes associated with thrombosis and anticoagulation in malignant SVCS. Patients with malignant SVCS diagnosed on computerized tomography (CT) were retrospectively included, indexed at diagnosis and followed for 6 months using medical records. The cohort included 183 patients with malignant SVCS of which 153 (84%) were symptomatic. Thirty of the 127 patients (24%) with a reviewable baseline CT had thrombosis of the SVC or tributaries at diagnosis. Patients with baseline thrombosis more often had symptomatic SVCS (p

KW - Superior vena cava syndrome

KW - Malignancy

KW - Thrombosis

KW - Anticoagulation

KW - MANAGEMENT

KW - OBSTRUCTION

U2 - 10.1007/s11239-018-1747-6

DO - 10.1007/s11239-018-1747-6

M3 - Article

C2 - 30255420

SN - 0929-5305

VL - 47

SP - 121

EP - 128

JO - Journal of Thrombosis and Thrombolysis

JF - Journal of Thrombosis and Thrombolysis

IS - 1

ER -